𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Behavioral effects of RO 41-9067: A novel D2 dopamine receptor agonist

✍ Scribed by Catherine Belzung; Paola Carletti; Flavia Angelucci; Stefano Puglisi-Allegra; Simona Cabib

Publisher
John Wiley and Sons
Year
1992
Tongue
English
Weight
505 KB
Volume
27
Category
Article
ISSN
0272-4391

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Antiparkinsonian effects of the novel D3
Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets: Mediation by D2, not D3, dopamine receptors
✍ Michael P. Hill; Paula Ravenscroft; Steven G. McGuire; Jonathan M. Brotchie; Ala πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 95 KB

L-dopa remains the most common treatment for Parkinson's disease. However, there is considerable interest in D3/D2 receptor agonists such as the novel agent S32504, since they exert antiparkinsonian properties in the absence of dyskinesia. An important question concerns the roles of D2 vs. D3 recept

Cortical effects of bromocriptine, a D-2
Cortical effects of bromocriptine, a D-2 dopamine receptor agonist, in human subjects, revealed by fMRI
✍ Daniel Y. Kimberg; Geoffrey K. Aguirre; Jessica Lease; Mark D'Esposito πŸ“‚ Article πŸ“… 2001 πŸ› John Wiley and Sons 🌐 English βš– 405 KB πŸ‘ 2 views

Studies of human subjects performing cognitive tasks on and off dopaminergic drugs have suggested a specific role of dopamine in cognitive processes, particularly in working memory and prefrontal "executive" functions. However, the cortical effects of these drugs have been poorly understood. We used